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Abstract 
In this study polymer-based microparticles are used to improve the therapeutic properties 
of ceftriaxone (CEF) and render them safer.  Poly-3-hydroxybutyrate (P3HB) and poly-3-
hydroxybutyrate/polyethylene glycol (P3HB-PEG)-based microparticles were prepared by two 
methods: a double emulsification technique and spray-drying. The microparticles were 
characterized in terms of size and zeta potential, morphology, total drug loading and drug 
release. The microparticles had spherical shapes with diameters of a size range from 0.74 to 1.55 
µm (emulsification technique) and from 3.84 to 6.51 µm (spray-drying); the encapsulation 
efficiency of CEF was around 63 % and 49 % for these methods respectively. The CEF release 
from microparticles obtained by spray-drying reached 100% after 150 hours, while for 
microparticles obtained by emulsification technique the total release of CEF did not exceed 34% 
after 312 hours. Antibacterial activity of the microparticles was evaluated against gram-positive 
and gram-negative bacterial strains. In general, the encapsulation of ceftriaxone in polymeric 
microparticles preserves the therapeutic efficacy of the CEF and provides a prolonged effect. 
Keywords: ceftriaxone, PH3B-microparticles, emulsification technique, spray-drying, 
drug release, antibacterial activity  
Introduction 
Scientific research and development of innovative drug delivery systems is a rapidly 
developing area worldwide. This trend is going to be strengthened in the future, as the cost of 
health care requires reducing costs and improving the effectiveness of existing dosage forms. 
Currently, we observe the crisis of antibiotic therapy not only due to a large number of resistant 
microorganisms, but also due to the lack of drugs that do not have resistance of one or other 
pathogens.  Moreover, bacteria appeared that are resistant to all existing antibiotics. In the past 
the pharmaceutical industry solved the problem of resistance by producing a new, more effective 
antibiotic. However, today there are no fundamentally new classes of antibiotics that are 
acceptable for clinical use and the development of new drugs usually takes about 10-15 years 
(Zhang Y. et al., 2013). Therefore, the interest of the pharmaceutical sciences is gradually 
shifting from the discovery of new chemicals to the optimization of their routes of administration 
and delivery.  
Thus, one of the drawbacks of classical antimicrobial therapy is that many intracellular 
bacteria are at rest or still, deactivating and dramatically changing the permeability of cell 
membranes, which affects the sensitivity to antibacterial agents. Therefore, such bacteria can 
persist for a long time. In addition, the most severe complications of antibiotic therapy are 
anaphylactic shock, allergic reactions, neurotoxic phenomena, dysbiosis, liver damage (Wright et 
al., 2013). 
One of the promising ways to solve this problem is the use of antibacterial drugs in the 
form of micro- and nanocarriers. Micro- and nanoparticles based on biopolymers are very 
convenient drug carriers. By placing antibiotics in carriers we can expect improved delivery to 
infected cells, increased bioavailability of drugs with poor absorption characteristics, prolonged 
drug residence time, targeted transport of therapeutic agents to specific organs, reduced toxicity 
and stability in the gastrointestinal tract (Raval et al., 2012; Xie et al., 2014; Hamzehloo et al., 
2017). A significant portion of antibiotics during the first 6 to 8 hours is mostly removed from 
the body. The use of microparticles allows to extend the elimination time (Xie et al., 2014; Zazo 
et al., 2016). 
Ceftriaxone (CEF) is a third-generation cephalosporin antibiotic that is effective mostly 
against gram-positive and gram-negative bacteria. CEF is a β-lactamase-resistant cephalosporin 
with a poor cellular penetration. Ceftriaxone is administered by slow intravenous infusion since 
it is poorly absorbed from gastrointestinal tract. (Manimekalai et al., 2017, Lipinski et al., 2001; 
Reddy et al., 2013; Shiffman et al., 1990). The literature describes examples of delivery systems 
for cephalosporin based on various materials. Thus, Kumar et al., 2016 demonstrated the efficacy 
of ceftriaxone-loaded solid lipid nanoparticles for gram-positive and gram-negative bacterial 
strains. In another paper the authors noted the pronounced antibacterial effect of conjugates of 
silver nanoparticles with ceftriaxone in the culture of various pathogenic strains of bacteria 
(Harshiny et al., 2015). Also, examples of prolonged forms of ceftriaxone in the form of 
conjugates based on poly (styrene-alt-maleic) anhydride (Najafi Moghadam et al., 2010),  
PEGylated microscopic lipospheres (Attama et al., 2009) and chitosan nanoparticles (Zaki et al., 
2012). 
Among the huge variety of polymers used to produce nano / microparticles, 
polyhydroxyalkanoates (PHA) has been the most widely used polymer in controlled release 
applications, including the encapsulation of different antimicrobial drugs (Li et al., 2005; Wang 
et al., 2007; Goreva et al., 2012; Vilos et al., 2012; Rodriguez-Contreras et al., 2013; Shershneva 
et al., 2014; Chen et al., 2015). This class of polyester attracts attention due to the presence of 
unique properties - biodegradation and biocompatibility. PHAs are thermoplastic, have less 
effect on pH values of tissues and have a longer in vivo degradation period, which allows them 
to be used for the development of prolonged drug delivery systems. It should be noted that spray 
drying is a popular way of depositing drugs in various polymer carriers, but with respect to PHA 
this method has not been properly developed. Single examples of the use of spray drying for 
producing microparticles based on polyhydroxybutyrate (P3HB) loaded with paracetamol (Re 
2006). However, publications on the preparation of PHA-based antibiotic-loaded microparticles  
by spray drying method have rarely been seen until now. 
Earlier we showed examples of the successful encapsulation of various antibacterial 
drugs in microparticles from P3HB and copolymers with P3HB / 3HV using the emulsion 
method (Goreva et al., 2012; Murueva et al., 2013). For the first time, the possibility of 
encapsulating an antitumor drug in a P3HB microparticle was demonstrated using the spray 
drying method (Murueva et al., 2016, Shershneva et al., 2018). The dependences of the 
characteristics of the microparticles (yield, average diameter, zeta potential) on the parameters of 
the production process (inlet temperature, polymer solution feed rate and polymer solution 
concentration) are established (Shershneva et al., 2014). 
Thus, the main objective of the study was to develop ceftriaxone delivery systems of as 
the polymeric microparticles. Microparticles from P3HB and blend with polyethylene glycol 
(PEG) were produced by a spray-drying technique and emulsion method. Furthermore, to 
evaluate the effects of these methods and chemical composition on the properties of the 
microparticles CEF release in vitro. Besides, cytotoxicity and antibacterial efficiency of CEF - 
encapsulated PHA microparticles were also investigated in vitro.  
Materials and Methods 
Materials  
P3HB with low molecular weight was produced at the Institute of Biophysics of the SB 
RAS by the microbial fermentation process (Table 1). The registered mark of material is 
"Bioplastotan
™
". PEG (35000 Da) was purchased Sigma-Aldrich (USA), ceftriaxone – Farm-
Center (Russia) (Table 1). 
Table 1. Materials and drug used in the work 
Material Formula Molecular 
weight, Da 
Manufacturer 
P3HB 
 
50 000 
Institute of Biophysics, 
Siberian Branch, Russian 
Academy of Sciences 
(RF Patent No. 2051967) 
PEG 
 
35 000 Sigma-Aldrich (USA) 
CEF 
 
554,58 Farm-Center (Russia) 
 
Preparation of microparticles by emulsion method (MPEM) 
Microparticles were prepared by the solvent evaporation technique, using (oil/water) 
emulsions. The emulsion contained 0.1 g P3HB or P3HB/PEG (50:50) in 10 ml of 
dichloromethane and 100 ml 0.5 % (w/v) PVA. The obtained emulsions were mechanically 
stirred at 24,000 rpm during 5 min (IKA Ultra-Turrax T25 digital high-performance 
homogenizer, Germany). All emulsions were continuously mixed mechanically for 24 hours 
until the solvent completely evaporated. Microparticles were collected by centrifuging (at 10,000 
rpm, for 5 min), rinsed 4 times in distilled water and lyophilic dryer in an Alpha 1–2 LD plus 
(Christ, Germany). 
The described above method was also used for loading CEF into microparticles. The CEF 
(10 mg) was dissolved in 1 ml of distillated water and added to the solution of  0.1 g P3HB or 
P3HB/PEG (50:50) in  dichloromethane  and the resulting emulsion was sonicated at  6 W for 2 
min (Misonix 3000, USA). Then obtained emulsions were added to 0.5 % (w/v) PVA solution at 
stirring at 24,000 rpm (IKA Ultra-Turrax T25 digital high-performance homogenizer, Germany). 
Centrifugation and washing conditions were similar to as described earlier. 
Preparation of microparticles by spray-drying (MPSD)  
Spray-dried microparticles were prepared from P3HB or P3HB/PEG (50:50) solutions in 
dichloromethane (400 mg, 40 ml) using Büchi B-290 Spray dryer (BÜCHI Laboratory 
Equipment, Switzerland, Flawil). In brief, a polymer solution was sprayed through a nozzle 
(diameter of 0.7 mm) at a feed rate 1.5 ml / min at the inlet temperature 75 °C. The value of the 
aspirator (current of argon) was supported at the maximum gas flow rate 35 m
3
/h. 
CEF-loaded microparticles were prepared by spray drying water/oil-emulsions. To the 
solutions of polymer were added an aqueous solution of CEF (80 mg / ml). And those emulsions 
were homogenized using sonication at a power of 6 W for 2 min. The obtained homogeneous 
emulsions were continuously stirred (700 rpm) and sprayed at the described above parameters. 
Characterization of microparticles 
Morphological analysis 
Scanning electron microscopy (SEM) analysis of the prepared CEF-loaded microparticles 
was carried out using the S-5500 (Hitachi, Japan).  The samples were sputter-coated with 
platinum using an electrical potential of 2.0 kV at 25mA for 6 min with a sputter coater K550X 
(Emitech, Quorum Technologies Ltd., UK). 
Process yield (%) 
The processing yields were defined as the percentage of the weight of microparticles 
(Wm) compared to the weight of polymer (Wp) in the initial solution as shown in Eq. (1):  
       (1) 
Measurement of the particle size and zeta potential  
About 5 mg of each sample was suspended in bidistilled water, sonicated at 6 W for 1 
min. The size distribution of the microparticles was determined with the principle of laser 
diffraction using a particle size analyzer at 25 ºC ± 1 ºC (Zetasizer Nano ZS, Malvern Ltd., UK). 
The average particle size measurements were studied in triplicates. The surface charge of 
microparticles was characterized by value of zeta potential, which was determined by the 
electrophoretic mobility of the particles in the suspension on Zetasizer Nano ZS. 
Drug encapsulation efficiency 
The amount of drug inclusion in the polymeric microparticles was determined by 
spectrophotometric analysis. The CEF-loaded MPSD were dissolved in dichloromethane and 
water was then added in a ratio 1:1. The resulting emulsion was mechanically stirred on a shaker 
to extract the CEF into water. An aqueous phase containing ceftriaxone was then taken and 
optical density measurements were made. CEF encapsulation efficiency of MPEM was measured 
according to the procedure described previously (Murueva et al., 2013). 
The quantity of CEF loaded into microparticles was determined on a UV-Vis 
spectrophotometer Cary 60 (Agilent Technologies, Selangor, Malaysia) by measuring the 
UV-Vis absorbance at 240 nm using pre-built calibration graphs. The experiment was carried out 
in triplicates. 
The encapsulation efficiency (EE) was defined as the percentage of the weight of drug in 
microparticles (Wm) compared to the initial weight of drug (Wi) as shown in Eq. (2): 
            (2) 
In vitro ceftriaxone release studies 
The controlled drug release from CEF-loaded microparticles was carried out in vitro. The 
microparticles were initially sterilized by UV radiation for 40 minutes and placed in a sterile 
centrifuge tubes, containing 10 ml of phosphate-buffered saline (PBS, pH 7.4). Those centrifuge 
tubes were exposed to thermostat at 37 °C (n=3). Microparticles were settled by centrifugation 
(10000 rpm, 10 min) and samples subjected to determine the amount of the drug released at 
different intervals. 1 ml samples were withdrawn from the solution to observe the change in CEF 
concentration by UV-Vis spectroscopy (Agilent Technologies, Malaysia). The amount of volume 
used from centrifuge tubes was replaced with fresh phosphate buffer. The amount of CEF in the 
supernatant was determined at 240 nm. Triplicate measurements were performed during every 
analysis. 
Cell culture  
In vitro cytotoxicity assay  
The determination of the possible toxicity of PHA microparticles of different chemical 
composition was investigated in experiments using the NIH 3T3 mouse fibroblast line, which 
was plated on microparticles (5 × 103 cells / cm2) placed in 24-well plates as described in 
Nakoaka R. [Nakaoka R. et al., 2002]. The suspensions of microparticles in phosphate buffer 
were used at a concentration of 2 mg / ml; 100 μl of a suspension of particles of each type were 
introduced into 24-well culture plates (Corning, USA). Polystyrene plates (Corning, USA) were 
used as a control. 
Culturing the fibroblasts was performed according to a standard procedure in a DMEM 
medium [Фрешни Р.Я., 2010], containing a 10% solution of embryonic bovine serum, a solution 
of antibiotics (streptomycin 100 μg / ml, penicillin 100 U / ml) in a CO2 incubator (New 
Brunswick Scientific, USA) at 5% CO2 in the atmosphere and 37 ° C. The medium was replaced 
every three days. 
The viability of NIH 3T3 cells was evaluated in a reaction with MTT. For this purpose, 
50 μl of a 5% MTT solution and 950 μl of the total nutrient medium were added to the well with 
each type of polymer. After 3.5 hours of culture the medium with the MTT solution was replaced 
with DMSO to dissolve the formed MTT formazan crystals. After 30 minutes the supernatant 
was transferred to a 96-well plate (Corning, USA) and the optical density was measured at a 
wavelength of 540 nm on the Bio-Rad 680 microplate photometer (Bio-Rad Laboratories Inc., 
США) . The number of cells was estimated from the calibration schedule. 
Microbiological evaluation 
The antibacterial activity of antibiotic-loaded microparticles (Ceftriaxone) was 
determined using the disc-diffusion method for Gram-positive bacteria Staphylococcus aureus 
and Gram-negative bacteria Escherichia coli. This method is based on the diffusion of an 
antibacterial drug from the carrier into a dense nutrient medium and inhibition of the growth 
zone of the culture [МУК 4.2.1890-04].   Susceptibility disk of ceftriaxone was used as the 
control (with a drug content of 0.03 mg, BioRad, France). The concentration of encapsulated 
ceftriaxone when microparticles were introduced into the cell culture as a suspension was 0.3 
mg. 
The Mueller-Hinton medium (BioRad, France) was diluted in distilled water (25 ml per 
dish) and heated until completely dissolved. The nutrient medium was then sterilized by 
autoclaving at 1 A and 121 ° C for 15 minutes. Petri dishes were filled with medium on a 
horizontal surface so that the thickness of the agar layer in the dish was on average 4 mm, and 
left at room temperature until completely solidified. 
To determine the sensitivity of the microorganisms, an inoculum corresponding to a 
density of 0.5 according to the McFarland standard and containing about 1.5 × 108 CFU / ml was 
used. The inoculation was performed with sterile cotton swabs with uniform strokes. After 15 
minutes, in the middle of the Petri dish, vertical wells with a diameter of 15 mm were made in 
agar and the microparticle suspension in physiological saline in a volume of 100 μl was 
excavated in them. The application of the disks was performed on agar without the formation of 
wells using sterile tweezers. Upon completion Petri dishes were left in a thermostat at 37 ° C.  
After a day, the diameter of the culture growth retardation zones was measured. 
Results and discussion 
In this study, polymer-based microparticles are used to improve the therapeutic properties 
of CEF and render them safer.  PHB- and PHB-PEG-based microparticles were prepared by two 
methods: a double emulsification technique and spray-drying (abbreviations are presented in 
Table 2).  
 
Characterization of microparticles 
Microparticles size and polydispersity index were determined using dynamic light 
scattering by analyzer of Zetasizer Nano ZS. Results revealed that microparticles had a size 
range from 0.74 to 1.55 µm (emulsion method) and from 3.84 to 6.51 µm (spray-dried); a 
negative zeta potential ranging from –17.8 to –28.0 mV and from –37.5 to –95.7 mV 
respectively (Table 2). It is advisable to assume that the difference in ζ potentials is probably due 
to the adsorption on the surface of the microparticles of polyvinyl alcohol, which is used in the 
emulsion method and absent in the spray drying method. 
Table 2 - Sample composition and characterization of the obtained microparticles 
 
Samples 
 
Process 
yield, % 
Particle 
size, µm 
PdI 
Zeta 
potential,  
mV 
Encapsulation 
efficiency, % 
Emulsification technique 
PEM P3HB 72.5 0.74 ± 18.82  0.187 ± 0.063 -17.8 ± 0.3  - 
PPEM P3HB-PEG 39.0 1.55 ± 0.05 0.167 ± 0.037  - 28.0 ± 0.4 - 
PCEM P3HB- CEF 71.4 0.89 ± 0.02 0.250 ± 0.003 - 22.3 ± 0.6 66.0 
PPCEM 
P3HB-PEG- 
CEF 
26.8 1.55 ± 0.01 0.297 ± 0.027 - 25.0 ± 0.1 60.5 
Spray-drying  
PSD P3HB 33.2 6.51 ± 0.47 0.211 ± 0.058  -95.7 ± 0.6  - 
PPSD P3HB-PEG 51.1 4.06 ± 0.38  0.318 ± 0.192 - 37.5 ± 2.2 - 
PCSD P3HB- CEF 85.7 4.21 ± 0.70 0.260 ± 0.118 - 48.0 ± 1.4 50.6 
PPCSD 
P3HB-PEG- 
CEF 
34.5 3.84 ± 0.27 0.224 ± 0.058 - 38.7 ± 1.2 47.0 
 
It was found that the addition of PEG leads to a decrease in process yield, an increase in 
average diameter and zeta-potential of MPEM. On the other hand, the availability of PEG in 
MPSD resulted in a decrease of size and an increase of zeta-potential. Thus, CEF loading did not 
significantly affect size characteristics and process yield of MPs. The deposition efficiency was 
about 60 % and 50 % for MPEM and MPSD, respectively. 
Fig.1 shows the SEM images of CEF-loaded MPs. It was found that additional of PEG 
had important influence on the surface morphologies and microstructures of MPs. So PCSD had a 
smooth surface, while the surface of the PPCSD was rough with availability of small pores.  
 
Figure 1. SEM images and size distribution of microparticles with CEF:  
a – PCEM; b – PPCEM; c – PCSD; d –  PPCSD (all images share the same scale bar) 
 
Consequently, the addition of PEG as surfactant most likely led to a decrease in the 
amorphization of substances in the spray-drying process. A similar effect of the PEG use in 
spray drying was noted in the review of Paudel et al. [2013]. Moreover, PPCEM were also 
characterized by a change in the structure upon the addition of PEG. However, in this case PEG 
was dissolved in the process of microparticles preparation, leading to the formation of deformed 
particles. According to Li et al. [2009] PEG influenced the formation of pores on the surface of 
microparticles, but only with the correct ratio PHB-PEG. When the ratio of PEG was excessively 
high, the erosion and dissolving effect were so strong that it was impossible to integrate 
microparticles [Li et al., 2009]. On the whole, from the micrographs of Fig. 1 it could be seen 
that the MPSD were spherical in shape and significantly larger in size than the MPEM. 
Study of the ceftriaxone release from MPs in vitro  
CEF release profiles from MPEM and MPSD are presented in Fig. 2. The mean amount of 
CEF released from PCSD and PPCSD was 51.3% and 39.1% respectively in the first 6 h and all the 
amount of drug from these formulations was released at approximately 150 h (Fig. 2a).  
Otherwise, CEF release from PCEM and PPCEM microparticles was seen retardant- the 
effect compared with PCSD and PPCSD (Fig. 2b).   In the first 6 h  9.4 % and 2.6 % of the CEF 
was released from the PPCEM and PCEM, respectively. Around 15 % of drug was released within 
48 h for PPCEM, while 4 % was released in the same period from PCEM. It is obvious that the 
drug release rate was increased when PEG was introduced into P3HB solution at emulsification 
technique. Likely, incorporation of PEG increased the release rate due to its high hydrophilicity 
and water solubility (Li et al., 2009, Parra et al., 2006; Rodrigues et al., 2005). As soluble filler, 
dissolution of PEG upon contact with a release medium would provide more channels for drug 
diffusion, inducing more drug molecules to be released.  After 312 h, 34 % and 10% of CEF 
were released from the PPCEM and PCEM microparticles, respectively.   
Earlier scientific literature reports that in the absence of biologic factors (enzymes, cells) 
the P3HB does not hydrolyze into carbon chains (Köse et al., 2003). This is due to the very high 
crystallinity and hydrophobic nature of polymer. Therefore, the rate of drug diffusion was 
substantially higher than that of polymer degradation, so the release profiles are more dependent 
on drug diffusion rather than on polymer degradation.  
 Figure 2. СEF release profile from (●) PC and (■) PPC microparticles prepared by 
emulsification technique (a) and spray-drying (b) 
 
The difference in the total release of CEF from MPEM and MPSD is most likely due to the 
fact that the drug molecules had different variants of localization in the particles and, as a 
consequence, different release rates. 
MPEM had a relatively low total drug release, which could be explained by the 
hydrophobicity of P3HB and dense packing of polymer chains in the transformation process of 
microdroplets into microparticles as a result, most of the drug molecules being inside the 
particles.  
At the same time, it was found that the increase of CEF release rates from PCSD and 
PPCSD can be related to the fact that the part of CEF solidifies separately during co-spray drying 
polymers. The remaining part of CEF may most probably be located near the surface. Therefore, 
drug molecules close to the surface leave the matrix very easily. Most likely, the drug release 
from PCSD and PPCSD in the first 3-6 hours is associated with solubilization of free CEF. The 
next phase of CEF release (48–312 h) was dominated by the diffusion mechanisms associated 
with the drug release from the surface structures of microparticles. 
In this way, these results confirm that it is possible to control the drug release by varying 
the method of preparation and chemical composition of MPs. 
In vitro cytotoxicity assay  
  
Microbiological evaluation 
The antibacterial activity of CEF, microparticles and empty particles was investigated 
against various bacterial strains including Escherichia coli and Staphylococcus aureus using the 
disk-diffusion method with the zones of inhibition (ZOI) to be measured (Fig. 4). 
 
Fig. 4 – Antibacterial activity of microparticles against E.coli and St.aureus 
 The antibacterial activity was compared against susceptibility disk of CEF. The 
antibacterial efficiency of free CEF was higher against E. coli in comparison to S. aureus, which 
is consistent with these minimum inhibitory concentrations. Herewith samples obtained by 
spray-drying showed higher antibacterial activity in comparison to disk (Table 3).  
The only sample obtained by the emulsification technique, PPCEM insignificantly 
suppressed growth of the more sensitive E. coli, while the remaining samples did not inhibit both  
E. coli and S. aureus (Table 3, Fig. 4). Probably this is due to the fact that the concentration of 
released CEF from PCEM and PPCEM was insufficient to suppress the growth of colonies. It is 
also worth noting that there have been some case studies of antibiotic-loaded PH3B, while their 
applications for cephalosporins cannot be easily found. For instance, Vilos et al. (2012) 
developed ceftiofur-loaded PHBV microparticles, which showed a slight bacterial inhibition 
during the first 5 hrs and a delay in the onset of the bacterial exponential growth E. coli.  
 
Table 3 – Antibacterial activity of in vitro microparticles against E.coli and St.aureus. 
Diameter of inhibition zones (mm) 
Test 
strain 
Disk of 
CEF 
PEM PPEM PCEM PPCEM PSD PPSD PCSD PPCSD 
E. coli 20.0 ± 0.3 - - - 5.1±0.2 - - 26.5±0.2 23.3±0.1 
S. aureus 6.2 ± 0.8 - - - - 16.0±0.3 12.0±0.1 26.7±0.2 22.0±0.3 
“-” – no zone of inhibition 
 
As a control, the activity of unloaded P3HB microparticles and the physiological 
solution, used for suspending the microparticles was checked. In both cases, no growth inhibition 
was observed in the analyzed cultures, which excludes the possibility of the influence of the 
chemical composition of the polymer and the medium used for suspending on the results of the 
efficacy of the encapsulated form of ceftriaxone (Table 3). The results obtained correlate with 
the data presented in the paper by Hema et al., in which the researchers confirmed the absence of 
antibacterial activity of films based on P (3HB), P (3HB-co-3HV) (6 mol%) and P (3HB-co-4HB 
) (70 mol%) with respect to E. coli and S. aureus [Hema R. et al., 2013]. 
 
Conclusion 
The outcome of this study is the development and characterization of CEF-loaded 
polymeric microparicles. P3HB- and P3HB-PEG-based microparticles were prepared by two 
methods: a double emulsification technique and spray-drying. The deposition efficiency of CEF 
was about 60 % and 50 % for MPEM and MPSD, respectively. It is shown that the surfactants used 
in the emulsion method affect on the electrophoretic activity of the microparticles. Therefore, the 
zeta potential of MPEM was lower than that of MPSD by an average of 3 times.  The addition of 
PEG to the P3HB solutions had important influence on the surface morphologies and 
microstructures of microparticles; however, the effect on drug release rate was clearly expressed 
only for MPEM. The total release of CEF from MPEM and MPSD had significant difference, which 
is most likely related to the localization of the drug molecules in the microparticles.  So, the CEF 
release of MPSD reached 100% after 150 hours, while for MPEM the total release of CEF did not 
exceed 34% for the entire observation period. 
The bactericidal potential of MPEM and MPSD with and without CEF was investigated 
against Escherichia coli and Staphylococcus aureus by disk-diffusion method. MPSD with CEF 
showed higher antibacterial activity (ZOI over 22.0 mm) in comparison to MPEM (ZOI not more 
than 5.1 mm). Thus, using various methods, the possibility of inclusion CEF with satisfactory 
indicators of the effectiveness of encapsulation, drug outflow and preservation of therapeutic 
activity in vitro into the composition of P3HB-carriers is shown, which allows to conclude that 
this class of polymers is promising for the development of long-acting dosage forms. 
 
